Ticker,Title,Link
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,8/29/2024 1:00:00 PM
APLS,"Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024",8/13/2024 11:15:00 AM
APLS,"Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Humacyte (HUMA) and Apellis Pharmaceuticals (APLS)",8/12/2024 11:12:54 AM
APLS,Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS),8/9/2024 1:29:41 PM
APLS,Buy Rating Affirmed for Apellis Pharmaceuticals on Strong Pegcetacoplan Trial Results and Positive Sales Forecast,8/8/2024 5:35:36 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),8/6/2024 10:05:00 PM
APLS,Apellis Pharmaceuticals: Adjusted Price Target and Hold Rating Amid Competitive Pressures and Modest Growth Prospects,8/5/2024 7:41:03 AM
APLS,Oppenheimer Remains a Buy on Apellis Pharmaceuticals (APLS),8/2/2024 12:33:05 PM
APLS,Buy Rating Justified for Apellis Pharmaceuticals Amidst Syfovre’s Growth and Prospective Market Expansion,8/1/2024 9:15:39 PM
APLS,Apellis Pharmaceuticals Q2 2024 Earnings Preview,7/31/2024 4:07:53 PM
APLS,Apellis Pharmaceuticals Strengthened Market Position and Buy Rating Following Competitor’s Clinical Failure,7/23/2024 6:15:35 PM
APLS,Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS),7/22/2024 10:42:30 AM
APLS,Jefferies Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS),7/19/2024 12:06:21 PM
APLS,"Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results",7/18/2024 1:00:00 PM
APLS,Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights,7/17/2024 7:01:43 PM
APLS,Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH) and Apellis Pharmaceuticals (APLS),7/11/2024 10:50:08 AM
APLS,Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting,7/9/2024 1:00:00 PM
APLS,What Analysts Are Saying About Apellis Pharmaceuticals Stock,6/28/2024 10:02:40 PM
APLS,SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA),6/10/2024 1:00:00 PM
APLS,Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference,6/5/2024 1:00:00 PM
APLS,Stifel Nicolaus Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS),6/4/2024 1:26:03 PM
APLS,Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts,5/28/2024 4:00:27 PM
APLS,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",5/25/2024 2:24:03 PM
APLS,Apellis Pharma up on phase 2 data for kidney disease treatment pegcetacoplan,5/24/2024 5:12:20 PM
APLS,Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Cara Therapeutics (CARA),5/23/2024 10:41:04 AM
APLS,Apellis Pharmaceuticals: A Strong Buy on Syfovre’s Performance and Market Potential,5/15/2024 1:08:37 AM
APLS,Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street,5/14/2024 2:00:00 PM
APLS,"Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX)",5/13/2024 11:00:33 PM
APLS,"Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)",5/10/2024 6:03:47 AM
APLS,In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals,5/8/2024 8:00:16 PM
APLS,Buy Rating Reaffirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Robust Financial Outlook,5/7/2024 8:15:17 PM
APLS,Notable earnings before Tuesday's open,5/6/2024 3:08:27 PM
APLS,Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting,5/1/2024 1:00:00 PM
APLS,Buy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potential,4/26/2024 3:45:25 PM
APLS,Maintaining Market Dominance: Strong Buy Rating on Apellis Pharmaceuticals with a Target Price of $85,4/25/2024 2:15:22 PM
APLS,"Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results",4/23/2024 1:00:14 PM
APLS,Wells Fargo Remains a Hold on Apellis Pharmaceuticals (APLS),4/18/2024 10:45:49 AM
APLS,Expert Ratings For Apellis Pharmaceuticals,4/15/2024 4:00:44 PM
APLS,Apellis Pharmaceuticals Hold Rating: Navigating Syfovre’s Mixed Reception and Emerging Competition,4/10/2024 6:19:33 AM
APLS,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)",4/9/2024 10:40:11 AM
APLS,Ocugen advances Phase 1/2 trial for eye disease candidate,4/5/2024 2:56:25 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),4/4/2024 10:05:00 PM
APLS,Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference,4/1/2024 1:00:00 PM
APLS,Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS),3/29/2024 8:30:13 AM
APLS,"PLAB, SMTC and WOOF are among after hour movers",3/28/2024 8:52:13 PM
APLS,Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals,3/27/2024 7:01:32 PM
APLS,"Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)",3/19/2024 11:10:09 AM
APLS,Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor,3/11/2024 12:00:00 PM
APLS,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Apellis Pharmaceuticals (APLS) and Iovance Biotherapeutics (IOVA)",3/7/2024 5:00:56 AM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),3/6/2024 10:05:00 PM
APLS,Wall Street Analysts Are Bullish on Top Healthcare Picks,3/4/2024 1:00:29 PM
APLS,Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings),2/28/2024 9:01:31 PM
APLS,Strong Syfovre Sales Drive Buy Recommendation for Apellis Pharmaceuticals with Revised $85 Price Target,2/27/2024 6:15:33 PM
APLS,Apellis Pharmaceuticals Q4 2023 Earnings Preview,2/26/2024 4:50:27 PM
APLS,"Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results",2/20/2024 1:00:00 PM
APLS,Apellis Pharmaceuticals Outperforms Astellas: A Strong Buy Recommendation,2/7/2024 1:38:58 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2/6/2024 10:05:00 PM
APLS,Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday,2/5/2024 2:09:27 PM
APLS,Investors growing more bullish on SMID cap biotech stocks,2/4/2024 10:16:46 PM
APLS,Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know,1/30/2024 4:01:02 PM
APLS,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Dexcom (DXCM) and Nanosonics Limited (OtherNNCSF)",1/29/2024 10:07:15 AM
APLS,Maintaining Buy Rating on Apellis Pharmaceuticals Amidst European Setback and Promising U.S. Market Prospects,1/27/2024 3:36:19 PM
APLS,Apellis: EU's CHMP Adopts Negative Opinion For Pegcetacoplan For GA; To Seek Re-Examination Of MAA ,1/26/2024 1:54:43 PM
APLS,Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday,1/24/2024 1:18:31 PM
APLS,Apellis Pharmaceuticals appoints COO,1/22/2024 1:15:34 PM
APLS,Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday,1/17/2024 2:19:50 PM
APLS,"Analysts Conflicted on These Healthcare Names: Legend Biotech (LEGN), Altimmune (ALT) and Apellis Pharmaceuticals (APLS)",1/12/2024 1:30:32 PM
APLS,Apellis Pharmaceuticals: Hold Rating Maintained Amid Mixed Performance and Market Uncertainty,1/11/2024 6:56:38 AM
APLS,Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (12 Ratings),1/9/2024 4:00:54 PM
APLS,TD Cowen Sticks to Their Buy Rating for Apellis Pharmaceuticals (APLS),1/8/2024 5:35:34 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),1/5/2024 10:05:00 PM
APLS,Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference,1/2/2024 1:00:00 PM
APLS,Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference,12/28/2023 1:00:00 PM
APLS,"Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday",12/22/2023 5:20:07 PM
APLS,"Analysts Offer Insights on Healthcare Companies: RxSight (RXST), TransMedics Group (TMDX) and Apellis Pharmaceuticals (APLS)",12/19/2023 12:10:48 PM
APLS,Micron Technology To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Friday,12/15/2023 2:15:33 PM
APLS,"US Stocks Eye 7-Day Winning Streak As Mortgage Rates Fall Below 7%, Yields Tumble: What's Driving Markets Thursday?",12/14/2023 7:58:49 PM
APLS,Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session,12/11/2023 7:12:59 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),12/6/2023 10:05:00 PM
APLS,Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch,12/5/2023 8:34:44 PM
APLS,"Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Apellis Pharmaceuticals (APLS) and Bausch + Lomb Corporation (BLCO)",12/4/2023 10:20:43 AM
APLS,Positive Outlook for Apellis Pharmaceuticals with Buy Rating and Anticipated Share Price Return,12/3/2023 4:36:26 PM
APLS,Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference,11/21/2023 1:00:00 PM
APLS,Goldman Sachs Says These 2 Healthcare Stocks Look Attractive — Here’s What Makes Them Each a ‘Buy’ Right Now,11/10/2023 8:04:00 PM
APLS,Apellis Pharmaceuticals (APLS) Buy Rating: Evaluating the Commercial Potential of Syfovre amid Retinal Vasculitis Concerns,11/9/2023 11:50:20 AM
APLS,Hold Rating on Apellis Pharmaceuticals Amidst Syfovre’s Success and Izervay’s Potential Competition,11/8/2023 5:54:21 AM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),11/6/2023 10:05:00 PM
APLS,Apellis Pharmaceuticals’ Syfovre Strengthens Dominance in GA Treatment: A Buy Rating Reiteration,11/5/2023 11:59:48 PM
APLS,SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA),11/4/2023 6:37:55 PM
APLS,Apellis Pharmaceuticals (APLS) Gets a Buy from Stifel Nicolaus,11/3/2023 2:07:27 AM
APLS,Buy Rating on Apellis Pharmaceuticals: Growth Potential from Syfovre Sales and European Market Expansion,11/2/2023 6:56:17 PM
APLS,Wall Street Analysts Are Bullish on Top Healthcare Picks,11/1/2023 4:40:12 PM
APLS,Here's what to expect from Apellis Pharmaceuticals's earnings,10/31/2023 3:01:13 PM
APLS,Oppenheimer Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS),10/27/2023 12:06:47 PM
APLS,"Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results",10/25/2023 1:00:00 PM
APLS,The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA),10/20/2023 2:00:00 PM
APLS,Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week ,10/17/2023 1:00:00 PM
APLS,"JPMorgan, Wells Fargo, Citigroup And Other Big Stocks Moving Higher On Friday",10/13/2023 4:49:48 PM
APLS,"Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), HashiCorp (HCP) and Apellis Pharmaceuticals (APLS)",10/12/2023 11:20:25 AM
APLS,‘There’s Good Value in the Market Now’: J.P. Morgan Suggests 2 Stocks to Buy — Including One With 80% Upside,10/10/2023 11:45:08 PM
APLS,"Analysts Offer Insights on Healthcare Companies: Castle Biosciences (CSTL), Axonics Modulation Technologies (AXNX) and Apellis Pharmaceuticals (APLS)",10/9/2023 5:20:39 AM
APLS,"Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023",10/6/2023 5:00:45 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/5/2023 10:05:00 PM
APLS,Apellis Pharmaceuticals Announces FDA Approval Of EMPAVELI Injector - Quick Facts ,10/2/2023 1:27:06 PM
APLS,Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session,9/27/2023 6:49:33 PM
APLS,Wall Street Analysts Are Bullish on Top Healthcare Picks,9/26/2023 10:20:10 AM
APLS,"Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023",9/25/2023 1:30:00 PM
APLS,"APLS NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS",9/24/2023 7:55:00 PM
APLS,Robert W. Baird Remains a Buy on Apellis Pharmaceuticals (APLS),9/21/2023 11:20:33 AM
APLS,"3 Best Stocks to Buy Now, 9/20/2023, According to Top Analysts",9/20/2023 12:38:04 PM
APLS,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Boston Scientific (BSX), Apellis Pharmaceuticals (APLS) and Healthequity (HQY)",9/19/2023 11:01:10 PM
APLS,"ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS",9/16/2023 10:12:00 PM
APLS,"Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023",9/15/2023 5:00:48 PM
APLS,Analyst Ratings for Apellis Pharmaceuticals,9/14/2023 8:00:21 PM
APLS,"ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS",9/9/2023 7:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),9/6/2023 10:05:00 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,9/5/2023 1:00:00 PM
APLS,"ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS",9/2/2023 4:00:00 AM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,8/30/2023 1:00:00 PM
APLS,Why Is Apellis Pharmaceuticals Stock Trading Lower Today?,8/29/2023 7:27:19 PM
APLS,"ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Apellis  Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS",8/25/2023 9:55:00 PM
APLS,Where Apellis Pharmaceuticals Stands With Analysts,8/24/2023 3:01:02 PM
APLS,S&P 500 Gains 1%; Analog Devices Posts Downbeat Results,8/23/2023 8:25:54 PM
APLS,Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection),8/22/2023 10:43:29 PM
APLS,Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now,8/21/2023 11:43:35 PM
APLS,"ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS",8/18/2023 2:00:00 AM
APLS,Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session,8/11/2023 7:47:10 PM
APLS,"ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS",8/10/2023 7:16:00 AM
APLS,Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session,8/7/2023 7:28:18 PM
APLS,"ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS",8/4/2023 9:28:00 PM
APLS,Where Apellis Pharmaceuticals Stands With Analysts,8/3/2023 11:00:23 PM
APLS,"Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2023",8/1/2023 5:00:36 PM
APLS,Why Apellis Pharmaceuticals  Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session,7/31/2023 9:30:12 PM
APLS,H.C. Wainwright Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS),7/30/2023 10:25:08 AM
APLS,Apellis says 'no indication' vision drug has led to eye inflammation,7/29/2023 11:16:25 PM
APLS,Apellis Pharmaceuticals Q2 2023 Earnings Preview,7/28/2023 7:54:01 PM
APLS,"APLS LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS",7/27/2023 11:30:00 PM
APLS,"Alphabet, Boeing, Union Pacific And Other Big Stocks Moving Higher On Wednesday",7/26/2023 6:17:26 PM
APLS,Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown,7/25/2023 9:39:10 PM
APLS,"Apellis Investigation Notification:  Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Investors",7/21/2023 10:25:00 PM
APLS,Apellis's Stock Under Pressure On Syfovre Safety Concerns: Analyst Slashes Price Target,7/20/2023 7:38:59 PM
APLS,Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session,7/18/2023 7:00:51 PM
APLS,Why Are Apellis Pharmaceuticals Shares More Than 20% Down Today?,7/17/2023 7:59:06 PM
APLS,"Analysts Are Bullish on Top Healthcare Stocks: Cingulate Inc (CING), Achieve Life Sciences (ACHV)",7/13/2023 11:40:10 AM
APLS,Iveric Bio falls amid concern about Astellas deal,6/28/2023 6:52:29 PM
APLS,Goldman Sachs Remains a Buy on Apellis Pharmaceuticals (APLS),6/27/2023 8:25:07 PM
APLS,The Latest Analyst Ratings for Apellis Pharmaceuticals,6/13/2023 2:04:57 PM
APLS,Annexon cut at BofA on mid-stage eye disease data,5/26/2023 1:23:02 PM
APLS,Apellis and Sobi to drop ALS candidate on Phase 2 setback,5/25/2023 12:10:01 PM
APLS,Novo Nordisk in pact with Life Edit Therapeutics for gene editing,5/24/2023 11:24:00 AM
APLS,"TIGR, APLS and LMFA among pre-market losers",5/16/2023 12:30:17 PM
APLS,Goldman Sachs Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS),5/15/2023 12:35:05 AM
APLS,"Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Pharvaris (PHVS) and Apellis Pharmaceuticals (APLS)",5/8/2023 8:10:10 AM
APLS,"Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations",5/5/2023 8:04:10 PM
APLS,"Apellis Pharmaceuticals GAAP EPS of -$1.56 misses by $0.10, revenue of $44.84M beats by $18.74M",5/4/2023 8:45:01 PM
APLS,Apellis Pharmaceuticals Q1 2023 Earnings Preview,5/3/2023 9:35:55 PM
APLS,Robert W. Baird Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS),5/1/2023 2:55:32 PM
APLS,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Ginkgo Bioworks Holdings (DNA), Apellis Pharmaceuticals (APLS) and IVERIC bio (ISEE)",4/24/2023 10:30:37 AM
APLS,"Analysts Conflicted on These Healthcare Names: Elevance Health (ELV), Apellis Pharmaceuticals (APLS) and Allogene Therapeutics (ALLO)",4/20/2023 10:30:39 AM
APLS,‘Let Your Winners Run’: Goldman Sachs Sees More Upside in These 2 Red-Hot Stocks,4/18/2023 7:24:58 PM
APLS,Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here's What You Need To Know,4/17/2023 7:00:34 PM
APLS,9 Analysts Have This to Say About Apellis Pharmaceuticals,4/14/2023 11:01:31 PM
APLS,Apellis Pharmaceuticals (APLS) Gets a Buy from Goldman Sachs,4/10/2023 1:45:06 AM
APLS,Apellis Pharmaceuticals may be worth $90-$100 a share in sale - analyst,4/3/2023 3:38:46 PM
APLS,Apellis Pharmaceuticals sees takeover interest from large pharma - Bloomberg,4/2/2023 8:32:28 PM
APLS,"Analysts Are Bullish on Top Healthcare Stocks: Apellis Pharmaceuticals (APLS), Immunocore Holdings (IMCR)",3/31/2023 12:21:23 PM
APLS,Apellis Pharmaceuticals' Empaveli sNDA action date extended by FDA,3/16/2023 3:34:42 AM
APLS,"Analysts Conflicted on These Healthcare Names: Horizon Therapeutics (HZNP), AnaptysBio (ANAB) and Apellis Pharmaceuticals (APLS)",3/2/2023 11:30:36 AM
APLS,Apellis Pharmaceuticals prices $350M in stock offering,2/23/2023 2:42:22 PM
APLS,Apellis Pharmaceuticals to raise $300M in stock and warrants offering,2/22/2023 1:15:13 PM
APLS,"Apellis Pharmaceuticals GAAP EPS of -$1.50 beats by $0.06, revenue of $22.66M misses by $1.86M",2/21/2023 9:57:26 PM
APLS,FDA Approves Apellis' Syfovre For Geographic Atrophy Treatment ,2/18/2023 2:19:54 PM
APLS,Apellis wins FDA nod for eye disorder therapy,2/17/2023 8:28:19 PM
APLS,"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",1/31/2023 8:33:01 PM
APLS,Biotech Stocks Facing FDA Decision In February 2023 ,1/29/2023 12:18:56 PM
APLS,Apellis appoints Baumal as Chief Medical Officer,1/5/2023 12:59:49 PM
APLS,"Apellis, Arvinas lower as Wells Fargo downgrades in 2023 biotech preview",1/3/2023 8:22:55 PM
APLS,"Catalyst watch: Tesla deliveries, CES reveals and healthcare updates lead off 2023",12/30/2022 7:00:00 PM
APLS,Robert W. Baird Remains a Buy on Apellis Pharmaceuticals (APLS),12/21/2022 5:05:31 AM
APLS,Apellis Pharma Submits MAA To European Medicines Agency For Intravitreal Pegcetacoplan ,12/16/2022 1:52:18 PM
APLS,Billionaire Israel Englander Snaps Up These 3 “Strong Buy” Stocks,12/12/2022 2:46:05 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,11/22/2022 10:05:00 PM
APLS,Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday,11/21/2022 11:58:39 AM
APLS,Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session,11/18/2022 7:15:49 PM
APLS,"Apellis, IVERIC bio cut to Hold at Jefferies; says Street overestimates GA market",11/10/2022 6:36:22 PM
APLS,5 Analysts Have This to Say About Apellis Pharmaceuticals,11/8/2022 7:21:46 PM
APLS,Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results,11/7/2022 10:05:00 PM
APLS,Notable earnings after Monday's close,11/6/2022 9:35:11 PM
APLS,Apellis Pharmaceuticals Q3 2022 Earnings Preview,11/4/2022 9:35:06 PM
APLS,Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA),11/3/2022 9:01:00 PM
APLS,"Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results",10/31/2022 9:05:00 PM
APLS,Biotech Stocks Facing FDA Decision In November 2022 ,10/26/2022 12:00:44 PM
APLS,7 Analysts Have This to Say About Apellis Pharmaceuticals,10/18/2022 3:26:01 PM
APLS,Citi lists four more value-creating events in biotech for this year,10/16/2022 4:00:13 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/7/2022 10:05:00 PM
APLS,Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday,10/4/2022 9:24:22 AM
APLS,"Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session",10/3/2022 6:27:22 PM
APLS,Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at...,9/30/2022 11:30:00 PM
APLS,Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference,9/12/2022 10:05:00 PM
APLS,Where Apellis Pharmaceuticals Stands With Analysts,9/8/2022 7:09:03 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),9/7/2022 10:05:00 PM
APLS,Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate,9/6/2022 6:47:11 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,9/1/2022 1:00:00 PM
APLS,Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday,8/25/2022 11:18:06 AM
APLS,Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA),8/24/2022 2:00:00 PM
APLS,Where Apellis Pharmaceuticals Stands With Analysts,8/9/2022 9:10:38 PM
APLS,Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results,8/8/2022 10:05:00 PM
APLS,Notable earnings after Monday's close,8/7/2022 9:35:38 PM
APLS,Apellis Pharmaceuticals Inc Registered Shs hosts conference call for investors,8/6/2022 2:45:00 PM
APLS,Apellis Pharmaceuticals Q2 2022 Earnings Preview,8/5/2022 9:35:12 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),8/4/2022 10:05:00 PM
APLS,7 Cheap Biotech Stocks to Buy Now,8/3/2022 8:42:38 PM
APLS,"Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results",8/1/2022 10:05:00 PM
APLS,Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock,7/27/2022 1:00:00 PM
APLS,Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday,7/20/2022 9:59:56 AM
APLS,Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher,7/19/2022 8:30:26 PM
APLS,Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting,7/14/2022 4:01:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),7/6/2022 10:05:00 PM
APLS,Citi eyes momentum in stocks for its North American Focus List,6/24/2022 1:22:09 PM
APLS,"The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral",6/22/2022 2:55:35 PM
APLS,Apellis/Sobi Empaveli shows benefit in rare blood disorder patients in new analyses,6/10/2022 1:28:25 PM
APLS,"The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data",6/8/2022 3:07:53 PM
APLS,"Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need",6/7/2022 1:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),6/6/2022 10:05:00 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,6/1/2022 10:05:00 PM
APLS,Expert Ratings for Apellis Pharmaceuticals,5/24/2022 11:29:36 PM
APLS,Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress,5/12/2022 5:05:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/6/2022 10:23:00 PM
APLS,Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference,5/5/2022 10:05:00 PM
APLS,Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results,5/4/2022 10:05:00 PM
APLS,Notable earnings after Wednesday's close,5/3/2022 9:35:38 PM
APLS,Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting,5/2/2022 9:30:00 PM
APLS,"Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results",4/26/2022 1:00:00 PM
APLS,Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA),4/21/2022 1:00:00 PM
APLS,Expert Ratings for Apellis Pharmaceuticals,4/14/2022 10:31:58 PM
APLS,Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference,4/4/2022 1:00:00 PM
APLS,Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares,3/28/2022 10:01:00 PM
APLS,Morgan Stanley projects about a third of biotechs will need financing in 2022,3/26/2022 4:00:28 PM
APLS,"The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL",3/24/2022 1:10:16 PM
APLS,Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock,3/23/2022 9:02:57 PM
APLS,Apellis Pharmaceuticals added to US Focus List at Citi; sees 79% upside,3/17/2022 4:18:08 PM
APLS,"The Daily Biotech Pulse:  Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study",3/16/2022 1:02:21 PM
APLS,Expert Ratings For Apellis Pharmaceuticals,3/7/2022 9:16:40 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,3/2/2022 1:00:00 PM
APLS,Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results,2/28/2022 10:05:00 PM
APLS,Notable earnings after Monday's close,2/27/2022 10:35:02 PM
APLS,Apellis Pharmaceuticals Q4 2021 Earnings Preview,2/25/2022 10:35:21 PM
APLS,"Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results ",2/22/2022 1:00:00 PM
APLS,Where Apellis Pharmaceuticals Stands With Analysts,1/11/2022 10:15:47 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),1/6/2022 10:05:00 PM
APLS,Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference,1/3/2022 1:00:00 PM
APLS,Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH,12/15/2021 1:00:00 PM
APLS,Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population,12/13/2021 5:45:00 PM
APLS,What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals,12/8/2021 5:26:13 PM
APLS,Analyst Ratings For Apellis Pharmaceuticals,11/29/2021 5:15:37 PM
APLS,Citi ups price target for Apellis on bullishness of pegcetacoplan for eye condition,11/24/2021 3:54:40 PM
APLS,Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares,11/18/2021 10:01:00 PM
APLS,"The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment",11/16/2021 2:30:12 PM
APLS,Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock,11/15/2021 10:01:00 PM
APLS,Cannabis stocks lead weekly healthcare gainers ahead of fresh legalization move,11/14/2021 2:00:00 AM
APLS,Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback,11/12/2021 1:00:00 PM
APLS,Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting,11/10/2021 1:00:00 PM
APLS,Where Apellis Pharmaceuticals Stands With Analysts,11/9/2021 7:20:49 PM
APLS,Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results,11/8/2021 10:01:00 PM
APLS,Apellis Pharmaceuticals Q3 2021 Earnings Preview,11/7/2021 9:35:00 PM
APLS,Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting,11/4/2021 2:17:31 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,11/3/2021 12:00:00 PM
APLS,"Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results",11/1/2021 12:00:00 PM
APLS,Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH,10/15/2021 1:17:00 PM
APLS,"Cramer Likes DraftKings, Skyworks, And These Automakers",10/7/2021 4:21:57 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/6/2021 10:05:00 PM
APLS,"ZBRA, FGEN, GOOGL and TCOM among after hours movers",9/30/2021 9:40:22 PM
APLS,Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference,9/20/2021 1:00:00 PM
APLS,Raymond James Upgraded This Biopharma Stock And Sees 44% Upside,9/13/2021 9:14:35 PM
APLS,Mid-Afternoon Market Update: Dow Slides Over 100 Points; Echo Global Logistics Shares Spike Higher,9/10/2021 9:07:34 PM
APLS,Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022,9/9/2021 10:05:00 PM
APLS,"Small biotechs warn Biden, lawmakers on drug price bill impact on R&D",9/8/2021 9:55:22 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),9/7/2021 10:05:00 PM
APLS,"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller / Chief Accounting Officer",9/3/2021 10:05:00 PM
APLS,Where Apellis Pharmaceuticals Stands With Analysts,8/19/2021 6:38:54 PM
APLS,New study reveals fresh safety concern linked to CRISPR gene editing,8/13/2021 1:42:31 PM
APLS,Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results,8/9/2021 10:01:00 PM
APLS,"The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight",8/8/2021 4:11:24 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),8/6/2021 10:05:00 PM
APLS,"Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results",7/29/2021 1:00:00 PM
APLS,Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock,7/26/2021 1:00:00 PM
APLS,"Align upgraded at Stephens, Novan surges on Cantor’s bullish call – in today's analyst action",7/9/2021 12:59:05 PM
APLS,Analyst Ratings For Apellis Pharmaceuticals,7/8/2021 5:43:09 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),7/7/2021 10:05:00 PM
APLS,10 Biggest Price Target Changes For Friday,7/2/2021 4:27:11 PM
APLS,"The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts",7/1/2021 2:06:57 PM
APLS,Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases,6/30/2021 10:15:00 PM
APLS,Seeking Alpha Catalyst Watch,6/25/2021 7:30:07 PM
APLS,"Apellis Pharmaceuticals to Host R&D Day on June 30, 2021",6/23/2021 1:00:00 PM
APLS,"The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO",6/16/2021 2:20:39 PM
APLS,"The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda",6/15/2021 2:07:38 PM
APLS,"The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts",6/11/2021 2:05:19 PM
APLS,"The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US",6/9/2021 3:14:20 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,6/3/2021 1:00:00 PM
APLS,"The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements",6/2/2021 2:20:24 PM
APLS,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,6/1/2021 11:31:09 PM
APLS,Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH,5/25/2021 1:00:00 PM
APLS,"Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021",5/21/2021 4:08:34 PM
APLS,58 Biggest Movers From Yesterday,5/18/2021 11:16:49 AM
APLS,Mid-Afternoon Market Update: Nasdaq Drops Over 100 Points; Apellis Pharmaceuticals Shares Spike Higher,5/17/2021 8:32:51 PM
APLS,Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH),5/15/2021 12:25:19 AM
APLS,"SMMT, CLSD, ADBE and AVDL among after-hours movers",5/14/2021 9:41:39 PM
APLS,Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress,5/12/2021 4:06:31 PM
APLS,"The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings",5/9/2021 4:20:33 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/7/2021 10:05:00 PM
APLS,Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates,5/1/2021 5:43:35 PM
APLS,Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results,4/28/2021 10:01:00 PM
APLS,"The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx",4/24/2021 3:24:00 PM
APLS,"Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021",4/21/2021 1:00:00 PM
APLS,Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting,4/16/2021 6:44:01 PM
APLS,Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy,4/13/2021 1:00:00 PM
APLS,"Oscar earns positive views as quiet period ends, Elanco defended at Citi despite safety concerns and more in today’s analyst action",3/29/2021 12:51:29 PM
APLS,Phase 3 data shows Apellis blood disorder drug besting Alexion's Soliris,3/18/2021 1:04:23 PM
APLS,Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH,3/17/2021 10:48:17 PM
APLS,Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy,3/10/2021 3:15:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),3/5/2021 10:05:00 PM
APLS,Apellis Provides Update on APL-9 for Severe COVID-19 ,3/4/2021 10:05:00 PM
APLS,Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results,2/25/2021 10:01:00 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,2/22/2021 2:00:00 PM
APLS,"The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings",2/20/2021 3:36:28 PM
APLS,"Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021",2/18/2021 10:05:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2/5/2021 10:05:00 PM
APLS,Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock,1/26/2021 11:00:00 PM
APLS,"Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021",1/21/2021 1:00:00 PM
APLS,"The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs",1/8/2021 1:25:06 PM
APLS,Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock,1/7/2021 12:55:00 PM
APLS,Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference,1/5/2021 1:00:00 PM
APLS,Stocks That Hit 52-Week Highs On Thursday,12/31/2020 4:15:08 PM
APLS,"The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data",12/30/2020 2:08:28 PM
APLS,Stocks That Hit 52-Week Highs On Tuesday,12/29/2020 4:32:13 PM
APLS,Stocks That Hit 52-Week Highs On Thursday,12/24/2020 4:15:22 PM
APLS,Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH,12/10/2020 12:00:00 PM
APLS,Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH,12/7/2020 4:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),12/4/2020 10:05:00 PM
APLS,Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx Conference,11/30/2020 1:00:00 PM
APLS,"Dosing underway for Apellis, Sobi's study of pegcetacoplan in muscle weakness",11/19/2020 12:50:32 PM
APLS,Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH,11/16/2020 1:00:00 PM
APLS,Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual,11/13/2020 4:40:00 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,11/11/2020 1:00:00 PM
APLS,Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting,11/5/2020 1:00:00 PM
APLS,Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results,11/2/2020 1:00:00 PM
APLS,"Apellis, Sobi inks licensing pact for systemic pegcetacoplan",10/27/2020 12:02:15 PM
APLS,Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan  in Patients with Geographic Atrophy (GA),10/19/2020 1:00:10 PM
APLS,Apellis on go with mid-stage COVID-19 study with C3 inhibitor,10/15/2020 1:45:29 PM
APLS,Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week ,10/9/2020 4:14:29 PM
APLS, Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/7/2020 10:05:10 PM
APLS,"Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need",10/5/2020 1:00:10 PM
APLS,Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA),10/3/2020 5:05:10 PM
APLS,Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit,9/24/2020 10:05:10 PM
APLS,Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020,9/21/2020 10:05:10 PM
APLS,Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH,9/15/2020 1:00:10 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),9/4/2020 10:05:10 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,9/2/2020 1:00:10 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),8/21/2020 10:05:10 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),8/7/2020 10:05:10 PM
APLS,Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results,7/31/2020 1:00:10 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),7/7/2020 10:05:10 PM
APLS,Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH),7/2/2020 2:00:10 PM
APLS,Apellis Pharmaceuticals to Present at the BMO 2020 Prescriptions for Success Healthcare Conference,6/16/2020 1:00:10 PM
APLS,"New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH",6/12/2020 8:30:10 AM
APLS,Apellis Announces Investor Conference Call to Discuss Phase 3 PEGASUS Data to be Presented at the 25th Annual Congress of the European Hematology Association (EHA),6/10/2020 11:34:40 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),6/5/2020 10:05:10 PM
APLS,Apellis Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference,6/4/2020 1:00:10 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/29/2020 10:05:10 PM
APLS,Apellis Pharma Initiates Phase 1/2 Study Of APL-9 In Patients With COVID-19 ,5/28/2020 1:44:22 PM
APLS,Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH),5/21/2020 1:00:10 PM
APLS,Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual Congress,5/14/2020 4:55:30 PM
APLS,Apellis Pharmaceuticals to Present at the BofA Securities 2020 Health Care Conference,5/8/2020 1:00:10 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/7/2020 10:05:10 PM
APLS,Apellis Pharmaceuticals Reports First Quarter 2020 Financial Results,4/29/2020 10:11:12 PM
APLS,Apellis Reports Analysis from Phase 1b Geographic Atrophy Study,4/28/2020 1:00:10 PM
APLS,Apellis is Outperforming the Pharmaceutical Sector,4/24/2020 1:34:13 PM
APLS,Paul Fonteyne Joins Apellis Board of Directors,4/6/2020 2:00:00 PM
APLS,Oppenheimer sees 26% downside in Intuitive Surgical in premarket action,4/1/2020 11:51:39 AM
APLS,Mizuho sees 86% upside in Sarepta in premarket analyst action,3/31/2020 11:18:15 AM
APLS,Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results,2/27/2020 10:44:10 PM
APLS,Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference,2/26/2020 1:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),1/16/2020 10:30:00 PM
APLS,Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares,1/13/2020 6:10:16 PM
APLS,Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock,1/9/2020 3:30:34 AM
APLS,"APLS Soars On PNH Data, ADXS On Track, TYME In Deal With Eagle, CVM On Watch ",1/8/2020 4:10:05 AM
APLS,Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock,1/7/2020 10:10:53 PM
APLS,Apellis Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference,1/2/2020 1:00:00 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,11/26/2019 1:00:10 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),11/15/2019 11:30:00 PM
APLS,Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week,11/8/2019 4:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),11/7/2019 11:30:00 PM
APLS,Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results,11/5/2019 1:30:00 PM
APLS,Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at  ASN Kidney Week 2019 ,10/11/2019 10:01:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/4/2019 11:30:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),9/27/2019 11:30:00 PM
APLS,Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference,9/26/2019 2:00:00 PM
APLS,Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration,9/18/2019 2:00:00 PM
APLS,Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes,9/16/2019 11:00:00 PM
APLS,Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes,9/12/2019 2:22:41 PM
APLS,Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes,9/11/2019 10:38:46 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),9/9/2019 11:00:00 PM
APLS,Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria,9/3/2019 2:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),8/28/2019 11:00:00 PM
APLS,Apellis Pharma : Scaling New Highs ,8/22/2019 12:43:12 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),8/16/2019 11:00:00 PM
APLS,Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results,7/31/2019 11:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),7/26/2019 11:30:00 PM
APLS,"Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer",7/22/2019 1:00:00 PM
APLS,Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies,7/18/2019 1:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),7/8/2019 11:30:00 PM
APLS,Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab,6/27/2019 1:39:53 PM
APLS,Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association...,6/15/2019 4:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),6/6/2019 11:30:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/24/2019 11:30:00 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,5/17/2019 2:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),5/13/2019 11:30:00 PM
APLS,Apellis Pharmaceuticals Reports First Quarter 2019 Business Update and Financial Results,5/8/2019 1:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),4/5/2019 10:30:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),3/22/2019 9:30:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),3/12/2019 11:00:00 PM
APLS,Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares,3/11/2019 5:01:00 PM
APLS,Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock,3/7/2019 1:00:00 PM
APLS,Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock,3/6/2019 10:00:00 PM
APLS,Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference,3/4/2019 10:00:00 PM
APLS,Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications,2/28/2019 4:00:00 PM
APLS,Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results,2/26/2019 11:00:00 PM
APLS,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2/13/2019 12:00:00 AM
APLS,Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria,2/11/2019 1:00:00 PM
APLS,Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia,2/5/2019 6:02:00 PM
APLS,"Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe",1/31/2019 3:00:00 PM
APLS,Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference,1/2/2019 1:00:00 PM
APLS,Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy,12/20/2018 10:01:00 PM
APLS,Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH,12/3/2018 7:01:00 PM
APLS,Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH,12/2/2018 6:01:00 PM
APLS,"Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer",11/20/2018 1:00:00 PM
APLS,Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results,11/13/2018 2:00:00 PM
APLS,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences,11/7/2018 10:30:00 PM
APLS,Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting,11/1/2018 3:50:17 PM
APLS,"EARS Tumbles, APLS Pauses Dosing, PTE Plunges On Short-seller Report Again ",10/19/2018 5:11:38 AM
APLS,Apellis Pharmaceuticals to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference,9/28/2018 3:00:00 PM
APLS,Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophy,9/12/2018 1:30:00 PM
APLS,Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy,9/4/2018 1:30:00 PM
APLS,"APLS To Report Data In 2H, CUR Abuzz, Shire Discontinues NASH Trial ",8/1/2018 7:52:05 AM
APLS,Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results,7/31/2018 10:30:00 PM
APLS,Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with Geographic Atrophy,7/24/2018 3:00:00 PM
APLS,Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™,6/26/2018 11:00:00 PM
APLS,"Apellis Pharmaceuticals to Host R&D Day on June 26, 2018",6/19/2018 2:30:00 PM
APLS,Apellis Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference,5/31/2018 1:00:00 PM
APLS,"INGN Soars On Revised Outlook, MRK Faces FDA In Sep., KPTI Taken By STORM ",5/1/2018 7:42:04 AM
APLS,Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results,4/30/2018 10:00:00 PM
APLS,Apellis Pharmaceuticals Announces Closing of Offering of Common Stock,4/24/2018 12:20:57 AM
APLS,BRIEF-Apellis Pharmaceuticals Announces Pricing Of Offering Of Common Stock,4/19/2018 3:30:43 AM
APLS,"APVO Walks The Talk, Eleven Bio Gains Over 13%, PADDOCK Data Boosts APLS ",4/17/2018 2:59:50 AM
APLS,BRIEF-Apellis Pharmaceuticals Announces Proposed Offering Of Common Stock,4/16/2018 11:13:45 PM
APLS,In The Spotlight: Apellis Pharma ,4/12/2018 10:09:57 AM
APLS,"ARNA Soars After-hours, Remoxy Now 2 Steps Away From Approval, APLS On Watch ",3/20/2018 8:16:36 AM
APLS,Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results,3/19/2018 9:30:00 PM
APLS,"DXR Soars On Big Volume, RXII Gets Attention, Busy Q2 Awaits SNDX ",3/15/2018 2:02:28 AM
APLS,"ZSAN Explodes, TTPH On Radar, APLS Catches Eyes, CERC Hits A High ",2/27/2018 2:04:42 AM
APLS,Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences,2/23/2018 1:00:00 PM
APLS,Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic AtrophyData supports biologic activity of APL-2 in reducing the growth rate of geographic atrophy,2/22/2018 2:44:44 PM
APLS,"KZIA Up 68% In 5 Days, APLS Bouncing Back, AKAO Clears A Hurdle, MDGL Abuzz ",1/31/2018 3:59:44 AM
APLS,"JUNO Flies On Takeover Rumor, PRTO For Long Haul, SUPN Gaining Strength ",1/18/2018 2:47:01 AM
APLS,"D-Day For ARDM Today, ALRN To Report Data In 1H18, DFFN On Watch ",1/11/2018 3:37:02 AM
APLS,"ARWR Hits A High, URGN Begins 2018 In Style, ARNA To Report Data In Q1 ",1/4/2018 2:12:44 AM
APLS,Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference,1/2/2018 1:00:00 PM
APLS,"APLS Sets Out Its Vision, APEN Gains Weight, Packed Year Ahead For DRNA ",12/22/2017 2:04:16 AM
APLS,Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2,12/20/2017 11:30:00 PM
APLS,"Apellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial Officer",12/19/2017 4:16:30 PM
APLS,"Busy Year Ahead For OMED, There's HOPE For GBT, APLS Sinks Below IPO Price ",12/13/2017 4:24:06 AM
APLS,Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest...,12/8/2017 10:34:10 PM
APLS,Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences,12/7/2017 12:00:00 PM
APLS,Apellis Pharmaceuticals Announces Closing of its Initial Public Offering,11/13/2017 10:05:00 PM
